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Multidrug-resistant 
tuberculosis
The ideal number of drugs needed and 
treatment duration are crucial issues 
in the management of multidrug­
resistant tuberculosis (MDR­TB). 
Thus, we read with interest the Article 
by the Collaborative Group for the 
Meta­Analysis of Individual Patient 
Data in MDR­TB treatment–2017,1 the 
results of which support our proposal,2 
from 2015, to classify anti­tuberculosis 
drugs on the basis of their toxicity, 
and sterilising or bactericidal activity.
The findings provide compel ling 
evidence on the use of fluoroquinolones 
(levofloxacin or moxifloxacin), plus 
linezolid and bedaquiline as the 
base for the initial treatment of 
tuberculosis strains with rifampicin 
resistance or multidrug resistance.1 
However, we believe that had these 
drugs been used from the start, some 
of the findings of the meta­analysis,1 
namely the optimal number of drugs 
needed to treat the cases (five) and 
treatment duration (18–20 months), 
would need to be refined. Both results 
were obtained because most of the 
drugs included in the regimens that 
had been evaluated by the meta­
analysis have no effect on treatment 
outcomes,1 and many show poor or nil 
bactericidal and sterilising activity.2–4 
Two or three susceptible drugs, with 
good bactericidal and sterilising 
activity, is known to be enough to 
treat almost all cases of tuberculosis, 
even in individuals with MDR­TB.5 
Moreover, treatment duration could 
be reduced to 9–12 months if two or 
three sterilising drugs are included in 
the regimen.2,3 Given that levofloxa­
cin or moxifloxacin, linezolid, and 
bedaquiline have good bactericidal and 
sterilising profiles,2,4 these three drugs, 
administered for 9–12 months, should 
theoretically be enough to cure 
rifampicin­resistant or MDR­TB.6 In 
cases of fluoroquinolone resistance, 
fluoroquinolone could be replaced 
by clofazimine or delamanid, as both 
have good sterilising activity.2,6 
We agree that clinical trials are 
needed to ascertain the optimal 
combination and treatment duration 
(because using only the required 
number of drugs would lower the 
toxicity and price of regimens) and to 
improve treatment adherence.
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